Albany Molecular Research Inc.
Join AMRIat Chemspec Europe this year in the SOCMA Pavilion (Booth #G01H), from June 24-25, 2015, in Cologne, Germany, to learn more about our API Manufacturing solutions.
Join Albany Molecular Research Inc. (AMRI) at Chemspec Europe this year in the SOCMA Pavilion (Booth #G01H), from June 24-25, 2015, in Cologne, Germany. Chemspec is the perfect opportunity to learn more about how we can provide you with the essential expertise to support the development and the cGMP manufacture of your custom and complex Active Pharmaceutical Ingredients (API).
To help you progress your complex compounds, our API Manufacturing business is at the ready to support the production of your complex, formulated drug product, from grams to hundreds of kilograms. Our global manufacturing footprint, which also includes manufacturing in India, provides you with access to global markets and low-cost manufacturing of APIs and intermediates.
Core Competencies Include:
- Niche APIs
- Potent Compounds
- Process Chemistry
- Chromatographic Separations
- Clinical Drug Substance
- Conjugation Chemistry
- Controlled Substances
- Commercial-Phase Validations
- Steroids, Prostaglandins & Vitamin D Analogs
High Potency & Pilot Plant Production
We provide full-service GMP-warehousing with ambient, USP, refrigerated and freezer storage conditions, and approach quality on a GMP continuum, ensuring the correct quality measures are in place for each stage of a drug development project. Our capabilities include hydrogenations, esterifications, Friedel-Crafts acylations, low-temperature Grignards, chlorination, bromination, Palladium-catalyzed couplings, chiral resolutions, peptide couplings and others.
Contact Details:
Albany Molecular Research Inc.
Email: Lisa.Peterson@amriglobal.comWeb Address: Click here to schedule a meeting with us at Chemspec Europe in Cologne, Germany
Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries
May 30th 2025In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.
Prokaryotics Licenses Gram-Negative Antibiotic Potentiator from Northern Antibiotics
June 26th 2025Prokaryotics will gain worldwide rights to develop, manufacture, and commercialize NAB741, a non-bioactive polymyxin designed to increase permeability of the outer membrane of Gram-negative bacteria.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
